ifnγ

TNF IFNγ-IN-1 (TGA) is a dual inhibitor of TNF and IFN-γ. TNF IFNγ-IN-1 has potential antioxidant and anti-inflammatory activities for neurodegenerative diseases such as Alzheimer.

The Anti-IFNγ Antibody (B133.5) is a chimeric mouse IgG1 kappa targeting human IFNγ. Its isotype control is designated as Mouse IgG1 kappa, Isotype Control.

4-Methoxycinnamaldehyde (p-Methoxycinnamaldehyde) is an active ingredient of Agastache rugosa.4-Methoxycinnamaldehyde has cytoprotective activity against respiratory syncytial virus (RSV) in human laryngeal carcinoma cell lines, and helps to control disease induced by RSV infection, with an IC50 of approximately 0.055 μg/mL. The IC50 was about 0.055 μg/mL.

PF-07038124 HCl is a selective and potent PDE4 inhibitor with an IC50 of 0.5 nM for PDE4B2.PF-07038124 HCl inhibits IL-13, IL-4, and IFNγ, and can be used in the study of skin disorders such as atopic dermatitis and plaque psoriasis.

RGS10 modulator-1 (compound 15) is an effective regulator of RGS10. It significantly reverses IFNγ-induced expression of both RGS10 protein and mRNA, as well as COX-2 mRNA and iNOS expression triggered by IFNγ.

N-Octanoyl dopamine surpasses dopamine in preserving the contractile function of donor hearts from brain-dead individuals. Additionally, N-Octanoyl dopamine inhibits cytokine production in activated T cells and reduces the expression of MHC-II and adhesion molecules in endothelial cells stimulated by IFNγ.

Itaconic acid prodrug-1 (Compound P2) is an orally active prodrug of Itaconic acid that efficiently delivers Itaconic acid to skin tissues upon oral administration. It exhibits immunomodulatory effects, significantly inhibiting Poly(I:C) IFNγ-induced inflammatory cytokines in human epidermal keratinocytes. Itaconic acid prodrug-1 is useful for research into alopecia areata and other inflammatory skin conditions.

TBK1-IN-2 (Compound A1) is a potent inhibitor of TBK1 with an IC50 of 775 pM. It binds to TBK1 through stable hydrogen bonding and π-π stacking interactions, thereby inhibiting the phosphorylation of IRF3. TBK1-IN-2 works in synergy with TNF/IFNγ to enhance immune-mediated tumor cell death and is applicable in cancer immunotherapy research.

GSK-2250665A is an interleukin-2-inducible T-cell kinase (Itk) inhibitor with a binding affinity of pKi = 9.2, GSK-2250665A demonstrates significant selectivity for Itk over Aurora B kinase and Bruton's tyrosine kinase (Btk), with pIC50 values of 6.4 and 6.5 respectively, while also showing limited activity against other kinases, and GSK-2250665A inhibits interferon-gamma (IFNγ) production in peripheral blood mononuclear cells (PBMCs), establishing it as a highly selective chemical probe for T-cell receptor signaling research and immune modulation studies.

Cycloartenyl ferulate, a typical triterpene alcohol, enhances natural killer (NK) cell-mediated anticancer immunity by binding to IFNγ receptor 1 (IFNγR1). Additionally, this compound exhibits multiple biological activities, including antioxidant, antiallergic, anti-inflammatory, and anticancer effects.

PF-07038124 is an inhibitor of PDE4. The IC50 value of PF-07038124 for PDE4B2 is 0.5 nM. PF-07038124 shows inhibitory activities against IFNγ, IL4, and IL-13 with IC50 values of 1.06, 4.1, and 125 nM, respectively [1].

TYK2-IN-12 (compound 30) is a selective, orally active inhibitor of TYK2 (tyrosine kinase 2) (Ki: 0.51 nM). It inhibits IL-12-induced IFNγ in human and mouse whole blood with IC50 values of 2.7 and 7.0 μM, respectively, and can be used to study psoriasis.

JAK-IN-19 is a potent JAK inhibitor with pIC50 values of 7.2 for PBMC (IFNγ) and 7.7 for HLF (Eotaxin). The compound also exhibits pIC50 values of 7.0 for VEGFR2 and 5.8 for Aurora B.

Feladilimab (GSK3359609) is an IgG4 monoclonal antibody that is an ICOS agonist. Feladilimab binds to ICOS-expressing T cells, induces IFNγ, and increases PD-1/L1 expression. Feladilimab has anti-tumor activity and can be used to study cancer.

XY-52 (Compound 32), an ST2 (Stimulation-2) inhibitor, exhibits IC50 values of 5.68 μM and 4.59 μM in the AlphaLISA and HEK-Blue assays, respectively. It promotes proinflammatory T-cell proliferation and diminishes plasma sST2 and IFNγ biomarkers in a graft versus host disease (GVHD) mouse model [1].

QL-1200186 is an orally active, selective TYK2 inhibitor that, upon dose-dependent oral administration, suppresses interferon-γ (IFNγ) production following interleukin-12 (IL-12) stimulation and markedly improves skin lesions in a psoriatic mouse model [1].

Soquelitinib (CPI-818) is a covalent, irreversible, oral and selective ITK inhibitor that preferentially inhibits Th2 cytokine production over Th1, inhibits in vivo tumor growth in mice, and decreases markers of T-cell exhaustion, resulting in an increase in tumor infiltration and up-regulation of CXCR3, IFNγ, TNFα, and CD107a expression in normal CD8 cells.

Icotrokinra is an orally bioavailable and highly selective antagonist of the interleukin-23 receptor (IL-23R), thereby interfering with IL-23-mediated signaling cascades. Icotrokinra inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells with an IC50 value of 5.6 pM, and it suppresses IL-23-induced interferon-gamma production in natural killer cells with an IC50 value of 18.4 pM. Icotrokinra further demonstrates anti-inflammatory effects in a rat TNBS-induced colitis model, making it a compound of interest in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease.

Anti-Mouse IFN gamma Antibody (XMG1.2) is a rat IgG1 kappa monoclonal antibody specifically targeting IFNγ in mice. The recommended isotype control for this antibody is Rat IgG1 kappa, Isotype Control.

Anti-Mouse IFN gamma Antibody (R4-6A2) is a rat-derived IgG1 kappa isotype antibody designed for in vivo targeting of mouse IFNγ. The recommended isotype control for this antibody is Rat IgG1 kappa, Isotype Control.

TLR2/6 agonist (also a putative TLR10 ligand). Activates NF-κB. Induces pro-inflammatory cytokines including IL-8, IL-1β, CCL20 and TNF-α in vitro. Synergizes with IFNγ to induce CXCL10 release from melanoma cells.